Delving into the Latest Updates on Beijing Sintong Biotech Co., Ltd. with Synapse

Overview

Tags

Respiratory Diseases

Infectious Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

mAChRs(Muscarinic acetylcholine receptor)	1

主要研究目的在健康成年女性受试者中于餐后情况下评价盐酸利托君片和Utemerin®的吸收速度和吸收程度，评价两制剂间是否具有生物等效性。次要研究目的评估受试制剂盐酸利托君片和参比制剂Utemerin®在健康成年女性受试者中的安全性。

[Translation]

Primary study objective To evaluate the absorption rate and extent of ritodrine hydrochloride tablets and Utemerin® in healthy adult female subjects after meals, and to evaluate whether the two preparations are bioequivalent. Secondary study objective To evaluate the safety of the test preparation ritodrine hydrochloride tablets and the reference preparation Utemerin® in healthy adult female subjects.

Start Date21 Apr 2024

Sponsor / Collaborator

Beijing Sintong Biotech Co., Ltd.

CTR20202691 / CompletedNot Applicable

一项在健康成年女性受试者中于餐后情况下进行的关于盐酸利托君片（利托君，10 mg，口服片剂）和Utemerin®（利托君，5 mg，口服片剂）的单剂量、随机、开放性、双周期、双交叉的生物等效性研究

[Translation] A single-dose, randomized, open-label, two-period, double-crossover bioequivalence study of ritodrine hydrochloride (ritodrine, 10 mg, oral tablet) and Utemerin® (ritodrine, 5 mg, oral tablet) in healthy adult female subjects under fed conditions

主要研究目的在健康成年女性受试者中于餐后情况下评价盐酸利托君片和Utemerin®的吸收速度和吸收程度，评价两制剂间是否具有生物等效性。次要研究目的评估受试制剂盐酸利托君片和参比制剂Utemerin®在健康成年女性受试者中的安全性。

[Translation]

Primary study objective To evaluate the absorption rate and extent of ritodrine hydrochloride tablets and Utemerin® in healthy adult female subjects after meals, and to evaluate whether the two preparations are bioequivalent. Secondary study objective To evaluate the safety of the test preparation ritodrine hydrochloride tablets and the reference preparation Utemerin® in healthy adult female subjects.

Start Date20 Jan 2021

Sponsor / Collaborator

Beijing Sintong Biotech Co., Ltd.

CTR20202690 / CompletedNot Applicable

一项在健康成年女性受试者中于空腹情况下进行的关于盐酸利托君片（利托君，10 mg，口服片剂）和Utemerin®（利托君，5 mg，口服片剂）的单剂量、随机、开放性、双周期、双交叉的生物等效性研究

[Translation] A single-dose, randomized, open-label, two-period, double-crossover bioequivalence study of ritodrine hydrochloride (ritodrine, 10 mg, oral tablet) and Utemerin® (ritodrine, 5 mg, oral tablet) in healthy adult female subjects under fasting conditions

主要研究目的在健康成年女性受试者中于空腹情况下评价盐酸利托君片和Utemerin®的吸收速度和吸收程度，评价两制剂间是否具有生物等效性。次要研究目的评估受试制剂盐酸利托君片和参比制剂Utemerin®在健康成年女性受试者中的安全性。

[Translation]

Primary study objective To evaluate the absorption rate and extent of ritodrine hydrochloride tablets and Utemerin® in healthy adult female subjects under fasting conditions, and to evaluate whether the two preparations are bioequivalent. Secondary study objective To evaluate the safety of the test preparation ritodrine hydrochloride tablets and the reference preparation Utemerin® in healthy adult female subjects.

Start Date18 Jan 2021

Sponsor / Collaborator

Beijing Sintong Biotech Co., Ltd.

100 Clinical Results associated with Beijing Sintong Biotech Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Sintong Biotech Co., Ltd.

Login to view more data

100 Deals associated with Beijing Sintong Biotech Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Sintong Biotech Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Login to view more data